Physician profile
Mark W Hodges
NPI 1710974209
$15,763.69
in general payments reported to CMS, 2019-2025
60 companies · $2,584 in 2025
The $2,584 reported for 2025 was more than what 95% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,542 · 2020: $1,811 · 2021: $2,653 · 2022: $2,168 · 2023: $2,604 · 2024: $2,401 · 2025: $2,584.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,490 · Education: $99.30.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,490.29 |
| Education | $99.30 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $2,708.29 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Abbvie INC. | $1,442.39 | 2021-2025 | |
| Novo Nordisk INC | $1,271.55 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Merck Sharp & Dohme LLC | $1,162.35 | 2019-2025 | Verquvo, Segluromet, Steglujan |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,094.66 | 2019-2025 | Jardiance, Synjardy |
| Pfizer INC. | $806.47 | 2019-2025 | |
| Lilly USA, LLC | $744.18 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Bayer Healthcare Pharmaceuticals INC. | $549.53 | 2022-2025 | |
| Glaxosmithkline, LLC. | $458.18 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $416.98 | 2019-2025 | Trulance, Xifaxan |
| Sanofi US Services INC. | $350.00 | 2021 | |
| Astellas Pharma US INC | $346.99 | 2021-2025 | Veozah |
| Takeda Pharmaceuticals U.S.A., INC. | $337.44 | 2019-2025 | Trintellix |
| Teva Pharmaceuticals USA, INC. | $336.97 | 2019-2021 | |
| Abbott Laboratories | $290.05 | 2020-2025 | Freestyle Libre 3 |
Show all 60 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $282.52 | 2019-2024 | |
| Biohaven Pharmaceuticals, INC. | $267.01 | 2021 | |
| Exact Sciences Corporation | $254.23 | 2023-2025 | Cologuard Collection Kit |
| Journey Medical Corporation | $235.29 | 2022 | |
| Biohaven Pharmaceutical Holding Company LTD. | $190.50 | 2022 | |
| Sanofi-Aventis U.S. LLC | $188.32 | 2019-2023 | |
| Amgen INC. | $178.37 | 2019-2025 | Otezla, Repatha, Otezla |
| Allergan, INC. | $172.31 | 2020 | |
| Janssen Pharmaceuticals, INC | $148.95 | 2019-2022 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $129.35 | 2023-2025 | Caplyta |
| Axsome Therapeutics, INC. | $123.54 | 2023-2025 | Sunosi, Auvelity |
| Dexcom, INC. | $106.19 | 2023-2024 | Dexcom G6 Transmitter |
| Vanda Pharmaceuticals INC. | $99.74 | 2025 | Fanapt, Hetlioz |
| E.R. Squibb & Sons, L.L.C. | $77.01 | 2019-2025 | Eliquis |
| Xeris Pharmaceuticals, INC. | $75.66 | 2023-2025 | Gvoke Hypopen, Recorlev |
| Supernus Pharmaceuticals, INC. | $69.74 | 2019-2025 | Qelbree, Xyosted |
| Otsuka America Pharmaceutical, INC. | $68.86 | 2024-2025 | Rexulti |
| Corcept Therapeutics | $66.43 | 2024-2025 | Korlym |
| Amarin Pharma, INC. | $63.03 | 2019-2021 | |
| Harmony Biosciences LLC | $61.20 | 2024-2025 | |
| Medtronic, INC. | $60.47 | 2021-2022 | |
| Renalytix Ai, INC. | $46.37 | 2023-2024 | Kidneyintelx Blood Collection Convenience Kit |
| Currax Pharmaceuticals LLC | $43.61 | 2020-2022 | |
| Lundbeck LLC | $36.29 | 2025 | Rexulti |
| Idorsia Pharmaceuticals US INC | $34.38 | 2022-2023 | Quviviq |
| Tolmar, INC. | $32.06 | 2023-2025 | Jatenzo |
| Genentech USA, INC. | $23.02 | 2021 | |
| Phathom Pharmaceuticals, INC. | $22.19 | 2024 | Voquezna |
| Verona Pharma, INC. | $20.71 | 2025 | Ohtuvayre |
| Kyowa Kirin, INC. | $20.42 | 2025 | |
| Cequr Corporation | $19.88 | 2025 | Cequr Simplicity |
| Kowa Pharmaceuticals America, INC. | $18.10 | 2025 | Zoryve |
| Sumitomo Pharma America, INC. | $17.82 | 2024 | Gemtesa |
| Ironwood Pharmaceuticals, INC | $17.71 | 2019 | |
| Tris Pharma INC | $17.71 | 2025 | Dyanavel Xr |
| Paratek Pharmaceuticals, INC. | $17.40 | 2025 | Xhance, Nuzyra |
| Inspire Medical Systems, INC. | $17.13 | 2024 | Inspire |
| Aimmune Therapeutics, INC. | $16.97 | 2025 | Zenpep |
| Vivus LLC | $16.42 | 2019 | |
| Intra-Sana Laboratories | $16.41 | 2025 | Reltone 400 Mg, Reltone 200 Mg, Glycate |
| Verity Pharmaceuticals INC. | $16.30 | 2025 | Tlando |
| Corium, LLC | $16.26 | 2023 | Azstarys |
| Clarus Therapeutics INC. | $15.96 | 2021 | |
| Halozyme INC | $13.92 | 2023 | |
| Nalpropion Pharmaceuticals LLC | $11.90 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Hodges listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.